Sherlock going strong with HC seeing seq. improvement Elevated RUB weighing on EBIT in 2022e and 2...
Q3 report due Friday, 28 October Sales SEK 268m, adj.
Q3e: sales up 23% y-o-y but margins remain pressured We expect 2023e to show improvements Small p...
We expect 36% order growth & 30% sales growth in Q3e EBIT margins to improve from here 44x 2023e E...
On the 6th of October 2022, Fluicell (“Fluicell” or the “company”) announced that the company has re...
Cline Scientific AB (”Cline” eller ”bolaget”) tillkännagav idag den 7:e oktober att bolaget initiera...
Redeye updates its estimates for the Q2 report due to three announced acquisitions during the quarte...
Redeye updates our expectations on melanoma and NMSC and includes Barrier detection to our estimates...
Redeye thinks yesterday’s deal between Seeing Machines and Magna will grant Seeing Machines a certai...
Q3 report due on Thursday, 10 November We lower ‘22e-‘24e sales by 6%/10%/8% We foresee Duni cont...
Kvartalsestimat I denna analysuppdatering väljer vi att för första gången publicera estimat på kvart...
Nedstängningarna i Kina verkar ha drabbat Mobile hårdare än vi förut trodde… Med tanke på att 98% av...
Redeye comments on Ultimovacs reporting a three-year survival OS rate of some 71% for cohort 1 of it...
Redeye is happy to see Powercell signing a deal with ZeroAvia for future volume production of fuel c...
Financing options being explored Directed share issue of SEK 23.
Redeye is currently reviewing our fair value range and estimates for Coala Life.
We forecast Q3 sales and EBIT down 16-80% y-o-y Strong USD weighs on GM – weak consumer hits top li...
Operational momentum – expect higher occupancy q-o-q Higher interest rate path leads to negative CE...
Local awareness may prove vital in times like this NOI +2-4% and CEPS -3-4% Trading at ~0.
Well-shielded from high inflation and interest rates Tenants still able to withstand large rent hik...
